Pietro Crispino - Concepedia

Author

Pietro Crispino

Sapienza University of Rome

Also Known As

Crispino P., Crispino, P., P CRISPINO, P Crispino, P. Crispino, Pietro Crispino

119

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Sapienza University of Rome Istituto Superiore di Sanità Ospedale Sandro Pertini

About

Pietro Crispino is an author at Sapienza University of Rome specializing in medicine, gastroenterology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	174
2	Gastroenterology	2	2	112
3	Public Health	1	1	13
4	Endocrinology	1	1	13
5	Epidemiology	1	1	13

Pietro Crispino

Publications

632

Citations

H-Index

Page 1

	Year	Citations
Azathioprine or methotrexate in the treatment of patients with steroid‐dependent or steroid‐resistant ulcerative colitis: results of an open‐label study on efficacy and tolerability in inducing and maintaining remission Omero Alessandro Paoluzi, Roberta Pica, Adriana Marcheggiano, Alimentary Pharmacology & Therapeutics	2002	136
Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study Omero Alessandro Paoluzi, Federico Iacopini, Roberta Pica, Alimentary Pharmacology & Therapeutics	2005	83
Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects Maria Carla Di Paolo, Omero Alessandro Paoluzi, Roberta Pica, Digestive and Liver Disease Functional Gastrointestinal DisorderMedicineLong-term TreatmentGastroenterologyDigestive System Diseases	2001	82
2‐Week Triple Therapy for <i>Helicobacter pylori</i> Infection is Better Than 1‐Week in Clinical Practice: a Large Prospective Single‐Center Randomized Study P. Paoluzi, Federico Iacopini, Pietro Crispino, Helicobacter	2006	76
Oral Mesalazine (5-ASA) Treatment May Protect Against Proximal Extension of Mucosal Inflammation in Ulcerative Proctitis Roberta Pica, Omero Alessandro Paoluzi, Federico Iacopini, Inflammatory Bowel Diseases	2004	48
One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication Federico Iacopini, Pietro Crispino, Omero Alessandro Paoluzi, Digestive and Liver Disease Helicobacter Pylori EradicationAntimicrobial ChemotherapyMedicineAntimicrobial ResistanceStandard Therapy	2005	31
A randomized trial comparing 4.8 vs. 2.4g/day of oral mesalazine for maintenance of remission in ulcerative colitis Roberta Pica, C. Cassieri, Andrea Cocco, Digestive and Liver Disease Food IntoleranceFunctional Gastrointestinal DisorderOral MesalazineGastroenterologyPharmacotherapy	2015	30
Increased thrombin generation and circulating levels of tumour necrosis factor‐<i>α</i> in patients with chronic <scp>Helicobacter pylori</scp>‐positive gastritis A. Consolazio, M Borgia, Domenico Ferro, Alimentary Pharmacology & Therapeutics	2004	26
Desmoplasia influenced recurrence of disease and mortality in stage III colorectal cancer within five years after surgery and adjuvant therapy Maddalena Zippi, Giorgio De Toma, G. Minervini, Saudi Journal of Gastroenterology	2017	24
Role of Desmoplasia in Recurrence of Stage II Colorectal Cancer within Five Years after Surgery and Therapeutic Implication Pietro Crispino, Giorgio De Toma, Antonio Ciardi, Cancer Investigation	2008	20

Page 1